Recent Advances across Diabetes and Obesity Management - Genetic TOE

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of Genetic TOE profiles life sciences trends across diabetes and obesity management. The corresponding patent scenario is depicted along with the industry interactions.The Genetic TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in

Table of Contents

Recent Advances across Diabetes and Obesity Management - Genetic TOETechnology ProfilesMicrobiome Regulator for Enhancing Blood Glucose ModulationEpigenetic Regulation for T2D ManagementInsulin Glargine and Lixisenatide Combination Therapy for T2DNew Class of GLP1-Glucagon Receptor Agonists for Diabetes and Obesity ManagementAppendixPatent ScenarioPatent Scenario (continued)Industry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.